SLC5A2 and atrial fibrillation: “SGLT2—Is in patients with type 2 DM undergoing AF ablation is associated with a lower risk of needing subsequent cardioversion, new AAD therapy, and re‐do AF ablation. This suggests that SGLT2‐Is may increase the likelihood of maintaining sinus rhythm after AF ablation in patients with type 2 DM and AF”